Floatz logo

Tirzepatide

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

UNC Lineberger Comprehensive Cancer Centerprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Arimidex
Memorial Sloan Kettering Cancer Center
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Tazemetostat
National Cancer Institute (NCI)
Phase 2CCC
Copanlisib
NRG Oncology
Phase 2CCC

View all 14 →

Same molecule, other indications

Tirzepatide is also rated in:

type 1 diabetes mellitusDormant
BBB
Indicative ·
78 / 100
View asset →
psoriatic arthritisDormant
BBB
Indicative ·
74 / 100
View asset →
diastolic heart failureDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →